NEW YORK, NY / ACCESS Newswire / August 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Exelixis, Inc. ("Exelixis" or "the Company") (NASDAQ:EXEL). Investors who purchased Exelixis securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/EXEL.
Investigation Details
On July 28, 2025, Exelixis issued a press release "report[ing] financial results for the second quarter of 2025" and "provid[ing] an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones." Among other items, Exelixis reported that net product revenues for cabozantinib were approximately 2% below the consensus estimate of $531.3 million. Exelixis also disclosed that "[b]ased on our evaluation of emerging data from the phase 2 portion of the STELLAR-305 study in advanced squamous cell carcinoma of the head and neck, emerging competition in this indication and assessment of other potentially larger commercial opportunities, we have made the decision not to proceed to the phase 3 portion of the trial." On this news, Exelixis’s stock price fell $7.45 per share, or 16.78%, to close at $36.94 per share on July 29, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Exelixis securities, you can assist this investigation by visiting the firm’s site: bgandg.com/EXEL. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_467716804/2457/2025-08-01T13:10:03